Track topics on Twitter Track topics that are important to you
Edison Investment Research - Pharmaceutical & healthcare - Antibe Therapeutics: Antibe’s lead drug, ATB-346, combines a hydrogen sulfide (H2S)-emitting molecule with naproxen, an off-patent non-steroidal anti-inflammatory drug (NSAID). The firm plans to start a double-blinded Phase IIb osteoarthritis (OA) study in July 2018, with data expected in Q418. The trial’s efficacy results can build on recent Phase IIb gastrointestinal (GI) safety data and position Antibe well to seek ATB-346 partnerships or out-licensing deals.
Original Article: Antibe Therapeutics (ATE) - Working towards a GI-safe NSAID drugNEXT ARTICLE
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...